Literature DB >> 12880143

Identification of lipoproteins of intestinal origin in human atherosclerotic plaque.

Sebely Pal1, Kishore Semorine, Gerald F Watts, John Mamo.   

Abstract

Apolipoproteins (apo) B48 and B100 are exclusive markers of lipoproteins derived from the intestine and liver, respectively. Lipoproteins of hepatic origin are causally related to atherosclerosis and are found in plaque. However, lipoproteins of intestinal origin have not previously been reported in human atherosclerotic tissue, although studies in animal models suggest that chylomicrons may contribute to arterial cholesterol entrapment. In this study, we report on the relative distribution of both apoB48 and apoB100 in human atherosclerotic tissue. Lipoproteins were isolated from human femoral and carotid endarterectomy samples, from varicose vein and aortic aneurysms. ApoB was determined by Western blot analysis and quantified based on the signal to apoB48 and apoB100 protein standards of known mass. ApoB48 and apoB100 were found in human carotid and femoral endarterectomy samples, but not in varicose vein or aortic aneurysm tissue. The level of apoB48 relative to hepatic lipoproteins (B100) was found to be much greater than would be predicted based on the relative plasma concentration and arterial exposure of the two lipoprotein groups. Intimal association was substantially greater in carotid endarterectomy samples compared to femoral, however, the ratio of chylomicrons to hepatic lipoproteins was greater in the latter. On the basis that chylomicron apoB48 was found in human atherosclerotic tissue and that each chylomicron particle contains substantial quantities of cholesterol, it is possible that the contribution of intestinal lipoproteins to atherosclerosis may be significant.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880143     DOI: 10.1515/CCLM.2003.120

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  25 in total

1.  Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance.

Authors:  Jean-Philippe Drouin-Chartier; André J Tremblay; Jean-Charles Hogue; Valéry Lemelin; Benoît Lamarche; Patrick Couture
Journal:  J Lipid Res       Date:  2018-06-26       Impact factor: 5.922

Review 2.  Dyslipidaemia of diabetes and the intestine.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  World J Diabetes       Date:  2015-07-10

3.  Triacylglycerol-rich lipoproteins derived from healthy donors fed different olive oils modulate cytokine secretion and cyclooxygenase-2 expression in macrophages: the potential role of oleanolic acid.

Authors:  V S Graham; C Lawson; C P D Wheeler-Jones; J S Perona; V Ruiz-Gutierrez; K M Botham
Journal:  Eur J Nutr       Date:  2011-06-17       Impact factor: 5.614

4.  Increased intestinal lipid absorption caused by Ire1β deficiency contributes to hyperlipidemia and atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Jahangir Iqbal; Joyce Queiroz; Yan Li; Xian-Cheng Jiang; David Ron; M Mahmood Hussain
Journal:  Circ Res       Date:  2012-05-03       Impact factor: 17.367

5.  Apolipoprotein A-V deficiency enhances chylomicron production in lymph fistula mice.

Authors:  Linda S Zhang; Min Xu; Qing Yang; Robert O Ryan; Philip Howles; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-01-23       Impact factor: 4.052

6.  The role of Niemann-Pick C1 - Like 1 (NPC1L1) in intestinal sterol absorption.

Authors:  Stephen D Turley
Journal:  J Clin Lipidol       Date:  2008-04       Impact factor: 4.766

7.  Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial.

Authors:  Jean-Philippe Drouin-Chartier; André J Tremblay; Marie-Claude Lépine; Valéry Lemelin; Benoît Lamarche; Patrick Couture
Journal:  Am J Clin Nutr       Date:  2018-01-01       Impact factor: 7.045

8.  Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.

Authors:  W Gao; Q Wang; S Yu
Journal:  J Endocrinol Invest       Date:  2016-04-12       Impact factor: 4.256

9.  Potassium selenocyanoacetate reduces the blood triacylglycerol and atherosclerotic plaques in high-fat-dieted mice.

Authors:  Shaoqin Liu; Fang Fang; Guanghui Fan
Journal:  Cardiovasc Diagn Ther       Date:  2019-12

10.  Postprandial Peaking and Plateauing of Triglycerides and VLDL in Patients with Underlying Cardiovascular Diseases Despite Treatment.

Authors:  Clarissa E Samson; Ana Lyza B Galia; Khristine Ivy C Llave; Manuel B Zacarias; Leilani B Mercado-Asis
Journal:  Int J Endocrinol Metab       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.